Incyte (NASDAQ:INCY) Stock, Quote.Headers.trade-ideas

Incyte

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Temu,App,Seen,On,The,Ipad,Screen.,Temu,Shop,App

Large Cap

News

Movers

Trading Ideas

BABA

INCY

INTU

Citigourp Global Markets 2% Protected Notes Linked To The Djia

ULTA

Large-cap stocks had a rough week, including Target, PDD Holdings, ZTO Express, Tenet Healthcare, Ulta Beauty, Intuit, Nokia, Alibaba, Santander, and Incyte.

Target, Alibaba And Temu Parent PDD Are Among Top 10 Large-Cap Losers Last Week (Nov 18-Nov 22): Are The Others In Your Portfolio?

Medtronic_Headquarters-Photo by Tony Webster via Wikimedia Commons

Earnings

Equities

Eurozone

Commodities

Intraday Update

Markets

CDRO

NWTN

PRFX

SMCI

TRNR

Gold Moves Higher; Medtronic Posts Upbeat Results

Wall Street ai5

Macro Economic Events

Bonds

Specialty ETFs

Economics

ETFs

$BTC

SPDR Dow Jones Industrial Average ETF Trust

iShares Trust Barclays 20+ Year Treasury Bond Fund

Select Sector SPDR-Consumer Discretionary

Wall Street managed to recover from a red start caused by heightened geopolitical tensions stemming from the ongoing Russia-Ukraine conflict.

Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What&#39;s Driving Markets Tuesday?

Incyte Corp

Biotech

General

Incyte To Present Late-Breaking Tafasitamab Data In Follicular Lymphoma At ASH 2024 Alongside 20 Oncology Portfolio Updates, Including Phase 3 inMIND Results And Virtual Analyst Event On December 12

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol start="1">
<li>Target Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) tumbled 17.83% after the company reported the third-quarter earnings miss, and analysts slashed the <a href="https://www.benzinga.com/node/42117500" target="_blank" rel="noreferrer noopener">price target on the stock</a>.</li>
<li>Temu parent PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) plummeted 12.22% after the company reported <a href="https://www.benzinga.com/node/42111158" target="_blank" rel="noreferrer noopener">worse-than-expected financial results</a>. Analysts cut <a href="https://www.benzinga.com/quote/pdd/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecast on the stock</a>.</li>
<li>ZTO Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTO#NYSE">ZTO</a>) stock fell 8.50% after the company reported third-quarter results and cut its FY24 <a href="https://www.benzinga.com/node/42076268" target="_blank" rel="noreferrer noopener">guidance for parcel volume</a>.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock dipped 7.54% after Raymond James downgraded the stock <a href="https://www.benzinga.com/quote/thc/analyst-ratings" target="_blank" rel="noreferrer noopener">from Strong Buy to Outperform</a>.</li>
<li>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>) fell 7.34% after Berkshire Hathaway <a href="https://www.benzinga.com/node/42013172">cut its position</a> in the stock.</li>
<li>Intuit Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) declined 6.94% after the company <a href="https://www.benzinga.com/node/42123997" target="_blank" rel="noreferrer noopener">reported second-quarter results</a>. Several analysts revised <a href="https://www.benzinga.com/quote/intu/analyst-ratings" target="_blank" rel="noreferrer noopener">the price forecasts on the stock</a>.</li>
<li>Nokia Corporation NYSE: NOK) stock decreased 6.28%. The company secured a multi-year, multi-billion USD contract extension <a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener">with </a><a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener">Bharti Airtel</a><a href="https://www.benzinga.com/node/42089876" target="_blank" rel="noreferrer noopener"> in India</a>.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) shares were down 6.16%. The company plans to issue U.S. dollars and Chinese yuan bonds to raise capital, repay existing debt, and support <a href="https://www.benzinga.com/node/42032495" target="_blank" rel="noreferrer noopener">an ongoing stock buyback initiative</a>.</li>
<li>Banco Santander (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAN#NYSE">SAN</a>) stock dipped 5.60%.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock declined 5.47% after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic does not <a href="https://www.benzinga.com/node/42070590" target="_blank" rel="noreferrer noopener">support further development</a>.</li>
</ol>
Photo via Shutterstock

<h3>Gainers</h3>
<ul>
<li>Sonoma Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNOA#NASDAQ">SNOA</a>) stock moved upwards by 26.4% to $3.26 during Tuesday's pre-market session. The company's market cap stands at $4.3 million. </li>
<li>Aclaris Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) shares increased by 19.1% to $3.74. The company's market cap stands at $267.1 million. </li>
<li>Alumis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALMS#NASDAQ">ALMS</a>) shares rose 15.74% to $10.0. The market value of their outstanding shares is at $544.0 million. The company's, Q3 earnings came out 4 days ago. </li>
<li>TFF Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) shares rose 15.41% to $0.42. The company's market cap stands at $1.4 million. </li>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares increased by 15.32% to $1.43. The company's market cap stands at $54.0 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) stock rose 14.36% to $1.1. The company's market cap stands at $26.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Apollomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLM#NASDAQ">APLM</a>) stock fell 16.3% to $0.16 during Tuesday's pre-market session. The market value of their outstanding shares is at $17.8 million. </li>
<li>Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock fell 12.31% to $67.5. The market value of their outstanding shares is at $13.0 billion. </li>
<li>Cytek Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) stock declined by 10.78% to $5.38. The market value of their outstanding shares is at $693.0 million. </li>
<li>Grifols (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares fell 10.42% to $8.26. The company's market cap stands at $5.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) shares decreased by 9.8% to $0.26. The company's market cap stands at $1.4 million. As per the press release, Q3 earnings came out 3 days ago. </li>
<li>Alkermes (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALKS#NASDAQ">ALKS</a>) stock decreased by 9.26% to $25.0. The company's market cap stands at $4.0 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACRS

ALKS

ALMS

APLM

CTKB

FRES

GCTK

GRFS

HCWB

SNOA

TFFP

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite gaining by around 1% on Tuesday.
The Dow traded down 0.03% to 43,374.79 while the NASDAQ rose 1.03% to 18,985.21. The S&amp;P 500 also rose, gaining, 0.49% to 5,922.41.
Check This Out: <a href="https://www.benzinga.com/24/11/42059659/this-apollo-global-management-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Leading and Lagging Sectors Information technology shares rose by 0.6% on Tuesday.
In trading on Tuesday, materials shares fell by 0.6%.
Top Headline
Medtronic Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>) reported better-than-expected results for its second quarter and raise its outlook.
The company posted second-quarter 2025 sales of $8.40 billion, beating the consensus of $8.27 billion. The medical device maker reported adjusted EPS of $1.26, beating the consensus of $1.25.
Medtronic raised its fiscal year 2025 organic revenue growth guidance to 4.75%-5%, up from the prior 4.5%-5%. If recent foreign currency exchange rates hold, 2025 revenue growth on an adjusted basis would be 3.4%-3.9%. Medtronic expects 2025 adjusted EPS guidance to be $5.44-$5.50 versus previous guidance of $5.42-$5.50 and consensus of $5.45.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares shot up 29% to $27.84 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Shares of PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) got a boost, surging 172% to $1.4600. The company announced a 1-for-4 reverse stock split.</li>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares were also up, gaining 30% to $3.30. The company, which makes specialty fitness equipment under the CLMBR and FORME brands, disclosed that Armah Sports Group‘s B_FIT is installing CLMBRs in three of its nine locations in Saudi Arabia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares dropped 12% to $1.06. NWTN received Nasdaq staff delisting determination for non-compliance with Listing Rule 5250(c)(1).</li>
<li>Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) were down 13% to $66.74 after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus does not support further development.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) was down, falling 11% to $6.77 after the company received a Nasdaq delisting notice due to its public reports rule.</li>
</ul>
Commodities In commodity news, oil traded down 0.1% to $69.12 while gold traded up 0.7% at $2,632.40.
Silver traded up 0.3% to $31.305 on Tuesday, while copper rose 0.6% to $4.1435.
Euro zone
European shares closed lower today. The eurozone's STOXX 600 fell 0.45%, Germany's DAX fell 0.67% and France's CAC 40 fell 0.67%. Spain's IBEX 35 Index fell 0.74%, while London's FTSE 100 fell 0.13%.
Hourly labor costs in the Eurozone rose by 4.6% year-over-year in the third quarter compared to a revised 5% gain in the prior quarter. Annual inflation in the Eurozone rose to 2% in October from 1.7% in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.51%, Hong Kong's Hang Seng Index gaining 0.44%, China's Shanghai Composite Index gaining 0.67%&nbsp; and India's BSE Sensex gaining 0.31%.
Malaysia&#8217;s trade surplus narrowed to MYR 12.0 billion in October from MYR 13.0 billion in the year-ago month.
Economics
<ul>
<li>Housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month.</li>
<li>U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/11/42060404/nvidia-to-rally-more-than-19-here-are-10-top-analyst-forecasts-for-tuesday-2">Nvidia To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Wall Street managed to recover from a red start caused by heightened geopolitical tensions stemming from the <a href="https://www.benzinga.com/topic/russia">ongoing Russia-Ukraine conflict.</a>
Ukraine launched its first U.S.-made missile strike on a Russian city, while Russian President Vladimir Putin adjusted the nation's nuclear doctrine to broaden scenarios for a potential response. Yet, Russian Foreign Minister Sergei Lavrov sought to assuage fears of a nuclear escalation, stating that a nuclear war is not something Russia is considering.
Amid the geopolitical noise, investors remained focused on corporate earnings. Walmart Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>), often regarded as a bellwether of consumer health, surpassed expectations for the recent quarter. The retailer&#8217;s stock surged 4%, hitting fresh all-time highs and boosting market sentiment.
At midday, both the S&amp;P 500 and Nasdaq 100 posted marginal gains, while blue-chip stocks showed a slight deceleration and small caps held steady.
In fixed income, longer-dated bond yields dipped, with the iShares 20+ Year Treasury Bond ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLT#NASDAQ">TLT</a>) climbing 0.5%. The U.S. dollar gained 0.1%, attempting to rebound after two consecutive sessions of losses.
Geopolitical risks lifted demand for commodities, with gold and oil rebounding 0.8% and 0.5%, respectively. Natural gas prices – as closely tracked by the United States Natural Gas Fund LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNG#NYSE">UNG</a>) – extended the rally, adding 2.6% after a 5.3% jump on Monday and hitting the highest levels since June. 
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) continued to display extraordinary strength, with the cryptocurrency breaking to a new all-time high of $93,931, underscoring robust market interest despite broader macro uncertainties.
<h2 class="wp-block-heading">Tuesday&#8217;s Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,610.47</td>
<td>0.3%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,907.68</td>
<td>0.2%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,309.75</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>43,316.79</td>
<td>-0.2%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 13:10 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent111924&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rose 0.2% to $589.41.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;fell 0.3% to $433.10.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.4% higher to $502.08.</li>
<li>The&nbsp;iShares Russell 2000 ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) fell 0.3% to $229.50.</li>
<li>The&nbsp;Technology Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) outperformed, rising 0.5%. The&nbsp;Energy Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) lagged, down 0.7%.</li>
</ul>
<h2 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h2>
<ul>
<li>Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) surged 22% after appointing BDO US as its auditor and submitting a compliance plan to Nasdaq, signaling a proactive effort to address delisting concerns. The news bolstered investor confidence in the company&#8217;s governance and market stability.</li>
<li>United Airlines Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) climbed 3.5%, reaching its highest level since December 2019, following a bullish call from TD Owen, which raised the stock's price target from $100 to $110.</li>
<li>Incyte Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NYSE">INCY</a>) plummeted over 14% after announcing that data from its Phase 2 clinical study failed to support further development, disappointing investors hoping for progress in its pipeline.</li>
<li>Valvoline Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VVV#NYSE">VVV</a>) dropped 8% in reaction to a weaker-than-expected earnings report, as the market digested concerns over the company&#8217;s growth trajectory and profitability.</li>
<li>Vertive Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) rallied 11.7% in reaction to price target raises from investment banks such as Deustsce Bank and Oppenheimer.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42069891/sp-500-to-reach-6500-by-end-of-2025-analysts-predict-could-it-spark-ma-revival">S&amp;P 500 To Reach 6,500 By End Of 2025, Analysts Predict: Could It Spark M&amp;A Revival?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Stocks Move Higher, Walmart Hits Record High, Natural Gas Reaches 5-Month Peak: What's Driving Markets Tuesday?

Incyte Shares Resume Trade

<a href="https://x.com/MarkKleinmanSky/status/1858942117827018868" title="https://x.com/MarkKleinmanSky/status/1858942117827018868">https://x.com/MarkKleinmanSky/status/1858942117827018868</a>

Watching Incyte; Sky News City Editor Mark Kleinman Posts On X "Merck Is The Latest Industry Giant To Be Linked To A Takeover Bid For Incyte, With Which It Collaborates On Several Drug Development Projects."

Incyte Shares Halted On Circuit Breaker To The Upside, Stock Now Down - 9.67%

Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) stock is trading lower on Tuesday after the company announced that data from its Phase 2 study does not <a href="https://www.benzinga.com//node/42069374">support further development</a>. 
The Details: The company&#8217;s Phase 2 study evaluated MRGPRX4 in cholestatic pruritus, however, the data does not warrant further development.
In addition, Incyte announced that the company is pausing enrollment in its ongoing Phase 2 study of MRGPRX2 in chronic spontaneous urticaria. The decision was made after discovering some issues in early testing. 
The company will work with the U.S. Food and Drug Administration to determine next steps.
How To Buy Incyte Shares
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Incyte's case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
Related Link: <a href="https://www.benzinga.com/government/regulations/24/11/42045345/us-stocks-rebound-tesla-rallies-bitcoin-soars-above-92000-whats-driving-markets-monday">US Stocks Rebound, Tesla Rallies, Bitcoin Soars Above $92,000: What&#8217;s Driving Markets Monday?</a>
INCY Price Action: At the time of writing, Incyte shares are trading 13.9% lower at $66.27, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Michal Jarmoluk from Pixabay

What's Going On With Incyte Shares Tuesday?

U.S. stock futures were lower this morning, with the Dow futures falling more than 250 points on Tuesday.
Shares of AECOM (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACM#NYSE">ACM</a>) fell sharply in today's pre-market trading following <a href="https://www.benzinga.com/quote/ACM/earnings">fourth-quarter results</a>.
The company reported better-than-expected earnings for its fourth quarter. The company&#8217;s quarterly earnings came in at $1.27 per share which beat the analyst consensus estimate of $1.24 per share. The company reported quarterly sales of $4.11 billion versus the analyst consensus estimate of $4.14 billion.
Aecom shares declined 3.3% to $105.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Hanmi Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) shares tumbled 20.9% to $20.24 in pre-market trading.</li>
<li>Guardian Pharmacy Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRDN#NYSE">GRDN</a>) fell 20.7% to $16.96 in pre-market trading.</li>
<li>Flushing Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIC#NASDAQ">FFIC</a>) declined 12.2% to $15.25 in pre-market trading.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell 10.3% to $68.98 in today's pre-market trading after the company issued an update on early Phase MRGPRX2 and MRGPRX4 programs.</li>
<li>Grifols, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRFS#NASDAQ">GRFS</a>) shares declined 9.1% to $8.38 in pre-market trading.</li>
<li>Nexxen International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXN#NASDAQ">NEXN</a>) shares fell 7.3% to $8.37 in pre-market trading after jumping over 20% on Monday.</li>
<li>Trump Media &amp; Technology Group Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) fell 5.8% to $30.86 in pre-market trading after jumping around 17% on Monday.</li>
<li>Globalstar, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSAT#NYSE">GSAT</a>) shares fell 5.8% to $1.61 in pre-market trading. Globalstar announced its board of directors authorized a reverse stock split of its common stock.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

Pre-Market Outlook

FFIC

GRDN

GSAT

HAFC

NEXN

Aecom Reports Q4 Results, Joins Incyte And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

On Monday, Incyte&nbsp;Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b42049159/incyte-provides-update-on-early-phase-mrgprx2-and-mrgprx4-programs" rel="noreferrer noopener">spontaneous urticaria (CSU)</a>.
The decision was made following the observation of certain in vivo preclinical toxicology findings.
These data have been shared with the FDA, and Incyte will work closely with the FDA to determine the next steps.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41637452/incytes-jakafi-demand-is-strong-analyst-upgrades-stock" rel="noreferrer noopener">Incyte&#8217;s Jakafi Demand Is Strong, Analyst Upgrades Stock</a>
Enrollment in the other INCB000262 proof-of-concept studies is complete. Data from all clinical studies will help inform its future development and guide the potential development of backup molecules.
In addition, data from the Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus (CP) does not support further development.
The company added the investigational drugs via the Escient Pharmaceuticals deal <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38388366/incyte-should-consider-significant-stock-buyback-and-prioritize-r-d-analyst-recomme" rel="noreferrer noopener">for $750 million</a>.
William Blair says the &#8216;update is clearly disappointing&#8217; as the proof-of-concept data across all three indications was anticipated in the first quarter of 2025.
The analyst has not included estimates for the molecule in the model yet. However, William Blair previously projected it could launch in 2029 and bring substantial sales for Incyte in the 2030s, as it&#8217;s being tested for major market opportunities with the potential to become a blockbuster.
&#8220;Although ‘547 was not the focus of the Escient acquisition, it is clearly negative to also see the discontinuation of the other clinical-stage program associated with the acquisition,&#8221; the analyst adds.
William Blair writes that before more information is released about the toxicology findings and next steps for the ‘262 program, investors are likely to focus on other key pipeline updates expected in 2025.
These include Phase 3 results for povorcitinib in hidradenitis suppurativa, due in early 2025, and initial data on mutant-specific inhibitors (mCALR and JAK2V617F) for myeloproliferative neoplasms later in the year. These developments could significantly impact Incyte&#8217;s long-term outlook.
Price Action: INCY stock fell 11.35% at $68.28 during premarket session at the last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/42054284/whats-going-on-with-mullen-automotive-stock-monday" target="_blank" rel="noreferrer noopener">What&#8217;s Going On With Mullen Automotive Stock Monday?</a></li>
</ul>

Analyst Color

Health Care

Analyst Ratings

Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining by around 100 points on Tuesday.
The Dow traded down 0.34% to 43,244.07 while the NASDAQ rose 0.53% to 18,892.31. The S&amp;P 500 also rose, gaining, 0.14% to 5,902.02.
Check This Out: <a href="https://www.benzinga.com/24/11/42059659/this-apollo-global-management-analyst-begins-coverage-on-a-bullish-note-here-are-top-5-initiations-for-tuesday">This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday</a>
Leading and Lagging Sectors Information technology shares rose by 0.2% on Tuesday.
In trading on Tuesday, materials shares fell by 0.9%.
Top Headline
Lowe's Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOW#NYSE">LOW</a>) posted better-than-expected earnings for its third quarter on Tuesday.
The company reported third-quarter adjusted earnings per share of $2.89 beating the street view of $2.82. Quarterly sales of $20.170 billion outpaced the analyst consensus estimate of $19.424 billion.
Lowe's has revised its fiscal year 2024 outlook for its adjusted earnings per share (EPS) guidance from a range of $11.70 – $11.90 to a range of $11.80 – $11.90, compared with the consensus estimate of $11.85. Additionally, the company raised its sales forecast from a range of $82.70 billion – $83.20 billion to a new range of $83.00 billion – $83.50 billion, compared with the consensus estimate of $83.05 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Super Micro Computer, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) shares shot up 28% to $27.54 after the company announced the appointment of BDO USA as its independent auditor and the filing of a compliance plan with Nasdaq.</li>
<li>Shares of PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) got a boost, surging 195% to $1.5999. The company announced a 1-for-4 reverse stock split.</li>
<li>Interactive Strength Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares were also up, gaining 48% to $3.75. The company, which makes specialty fitness equipment under the CLMBR and FORME brands, disclosed that Armah Sports Group‘s B_FIT is installing CLMBRs in three of its nine locations in Saudi Arabia.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NWTN Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) shares dropped 12% to $1.06. NWTN received Nasdaq staff delisting determination for non-compliance with Listing Rule 5250(c)(1).</li>
<li>Shares of Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) were down 11% to $68.17 after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus does not support further development.</li>
<li>Codere Online Luxembourg, S.A. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDRO#NASDAQ">CDRO</a>) was down, falling 9% to $6.93 after the company received a Nasdaq delisting notice due to its public reports rule.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $69.58 while gold traded up 0.6% at $2,630.60.
Silver traded up 0.1% to $31.255 on Tuesday, while copper fell 0.3% to $4.1080.
Euro zone
European shares were lower today. The eurozone's STOXX 600 fell 0.91%, Germany's DAX fell 1.28% and France's CAC 40 fell 1.26%. Spain's IBEX 35 Index fell 1.47%, while London's FTSE 100 fell 0.36%.
Hourly labor costs in the Eurozone rose by 4.6% year-over-year in the third quarter compared to a revised 5% gain in the prior quarter. Annual inflation in the Eurozone rose to 2% in October from 1.7% in September.
Asia Pacific Markets
Asian markets closed higher on Tuesday, with Japan's Nikkei 225 gaining 0.51%, Hong Kong's Hang Seng Index gaining 0.44%, China's Shanghai Composite Index gaining 0.67%&nbsp; and India's BSE Sensex gaining 0.31%.
Malaysia&#8217;s trade surplus narrowed to MYR 12.0 billion in October from MYR 13.0 billion in the year-ago month.
Economics
<ul>
<li>Housing starts in the U.S. declined by 3.1% to 1.311 million in October versus a revised 1.353 million in the previous month.</li>
<li>U.S. building permits declined by 0.6% to an annual rate of 1.416 million in October.</li>
</ul>
Now Read This:
<ul>
<li> <a href="https://www.benzinga.com/24/11/42060404/nvidia-to-rally-more-than-19-here-are-10-top-analyst-forecasts-for-tuesday-2">Nvidia To Rally More Than 19%? Here Are 10 Top Analyst Forecasts For Tuesday</a></li>
</ul>

Nasdaq Gains 100 Points; Lowe's Earnings Beat Views

RBC Capital analyst Brian Abrahams maintains Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Sector Perform and lowers the price target from $80 to $74.

Price Target

RBC Capital Maintains Sector Perform on Incyte, Lowers Price Target to $74

Cantor Fitzgerald analyst Eric Schmidt reiterates Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) with a Neutral.

Reiteration

Cantor Fitzgerald Reiterates Neutral on Incyte

WIIM

Incyte shares are trading lower after the company announced that data from its Phase 2 study evaluating MRGPRX4 (INCB000547) in cholestatic pruritus does not support further development.

Shares of Symbotic Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYM#NASDAQ">SYM</a>) rose sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/11/42049125/symbotic-stock-rallies-after-strong-q4-results-details">better-than-expected fourth-quarter financial results.</a>
Symbotic reported quarterly earnings of five cents per share, which beat the analyst consensus estimate of three cents. Quarterly revenue came in at $576.76 million, which beat the analyst consensus estimate of $470.27 million and is an increase over sales of $391.88 million from the same period last year.
Symbotic shares jumped 28.6% to $39.30 in the pre-market trading session.
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>PainReform Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRFX#NASDAQ">PRFX</a>) gained 165.4% to $1.42 in pre-market trading. PainReform announced a 1:4 reverse share split of the company&#8217;s ordinary shares will take effect after the closing bell on Wednesday, Nov. 20.</li>
<li>noco-noco Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNC#NASDAQ">NCNC</a>) rose 115.5% to $0.2090 in pre-market trading after gaining around 9% on Monday.</li>
<li>TFF Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TFFP#NASDAQ">TFFP</a>) gained 49.9% to $0.5457 in pre-market trading. TFF Pharmaceutical recently announced it will wind down its operations.</li>
<li>Volato Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#NYSE">SOAR</a>) gained 49.4% to $0.3153 in pre-market trading. Volato Group shares gained around 4% on Monday after the company reported a year-over-year increase in third-quarter financial results.</li>
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) gained 33.9% to $1.66 in pre-market trading. HCW Biologics announced a $6.9 million direct offering and private placement priced above market.</li>
<li>Quantum Computing Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) gained 18.7% to $2.84 in pre-market trading after dipping 23% on Monday. The company recently disclosed a securities purchase agreement to sell 16 million shares of common stock at $2.50 per share in a registered direct offering.</li>
<li>J-Long Group Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JL#NASDAQ">JL</a>) gained 13.8% to $0.42 in pre-market trading after declining around 4% on Monday.</li>
<li>Zenvia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZENV#NASDAQ">ZENV</a>) climbed 13.7% to $1.32 in pre-market trading after the company posted third-quarter results.</li>
<li>Fresh2 Group Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) gained 9.5% to $1.0400 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Hanmi Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAFC#NASDAQ">HAFC</a>) shares tumbled 20.9% to $20.24 in pre-market trading.</li>
<li>Guardian Pharmacy Services, Inc. (NYSE: GRDN fell 20.7% to $16.96 in pre-market trading.</li>
<li>Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) shares fell 16.5% to $0.40 in pre-market trading. Helius Medical Technologies shares dipped around 9% on Monday after the company announced it initiated the process to explore a range of strategic alternatives.</li>
<li>Eco Wave Power Global AB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WAVE#NASDAQ">WAVE</a>) shares fell 15.1% to $8.01 in pre-market trading. Eco Wave Power Global shares jumped around 44% on Monday after the company announced it received the final Nationwide Permit from the U.S. Army Corps of Engineers.</li>
<li>AtlasClear Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATCH#NYSE">ATCH</a>) dipped 14.9% to $0.1870 in pre-market trading. AtlasClear shares jumped 22% on Monday higher after the company reported a year-over-year increase in first-quarter financial results.</li>
<li>Flushing Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIC#NASDAQ">FFIC</a>) declined 12.2% to $15.25 in pre-market trading.</li>
<li>Eterna Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ERNA#NASDAQ">ERNA</a>) fell 12.1% to $0.6036 in pre-market trading after dipping 18% on Monday.</li>
<li>Enveric Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) fell 11.2% to $0.3135 in pre-market trading after declining around 5% on Monday.</li>
<li>CleanCore Solutions, Inc. (NYZE: ZONE) shares dipped 9.4% to $1.55 in pre-market trading. CleanCore Solutions recently announced the launch of a pilot program with an international hotel chain.</li>
<li>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) fell 10.3% to $68.98 in today's pre-market trading after the company issued an update on early Phase MRGPRX2 and MRGPRX4 programs.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/42035732/jim-cramer-super-group-basic-materials-stock-is-very-hard-to-own-here">Jim Cramer: Super Group Finally &#8216;Broke Out,&#8217; This Basic Materials Stock Is &#8216;Very Hard To Own Here&#8217;</a></li>
</ul>

ATCH

ENVB

ERNA

HSDT

NCNC

QUBT

SOAR

WAVE

ZENV

ZONE

Why Symbotic Shares Are Trading Higher By Over 28%; Here Are 20 Stocks Moving Premarket

Incyte Says Data From Phase 2 Study Evaluating MRGPRX4 (INCB000547) In Cholestatic Pruritus Does Not Support Further Development

The decision was made following the observation of certain in vivo preclinical toxicology findings.
These data have been shared with the U.S. Food and Drug Administration (FDA) and Incyte will work closely with the FDA to determine next steps.
&nbsp;
&nbsp;

Incyte To Pause Enrollment In Ongoing Phase 2 Study Of MRGPRX2 (INCB000262) In Chronic Spontaneous Urticaria;

<a href="https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html" title="https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html">https://unemon.com/ResearchEasy/202411_INCY/20241115_INCY_Takeover_POA.html</a>

Rumors

Watching Incyte; Traders Circulate Research Report From Unemon Suggesting Novartis Emerges As The Ideal Acquirer, Says "Would Not Be Surprised To See A $105-$110 Deal In The Coming Weeks"

16 analysts have shared their evaluations of Incyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Incyte, revealing an average target of $73.69, a high estimate of $97.00, and a low estimate of $52.00. Observing a 6.41% increase, the current average has risen from the previous average price target of $69.25. 
<img src="https://www.benzinga.com/files/images/story/2024/1731614438_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Incyte. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$68.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$97.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Vikram Purohit</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$69.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$70.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$72.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Jay Olson</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$82.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$71.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Evan Seigerman</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Underperform</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$90.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Srikripa Devarakonda</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$74.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Michael Schmidt</td>
<td>Guggenheim</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$68.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$67.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Incyte. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Incyte compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Incyte's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Incyte's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/INCY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Incyte analyst ratings.</a>
<h2>Unveiling the Story Behind Incyte</h2>
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
<h3>Understanding the Numbers: Incyte's Finances</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.81%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Incyte's net margin is impressive, surpassing industry averages. With a net margin of 9.36%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Incyte's ROE stands out, surpassing industry averages. With an impressive ROE of 3.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Incyte's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.2%, the company showcases efficient use of assets and strong financial health.
Debt Management: Incyte's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Incyte

Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1. STOCK NEWS: Walmart (WMT) provided a "beat and rai...

Walmart higher, Lowe's lower after earnings: Morning Buzz

13:35 EST Incyte (INCY) trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving break...

Incyte trading halted, volatility trading pause

Incyte seesaws on report of potential Merck takeover interest

Mark Kleinman, Sky News' City editor, posted on X, the service formerly known as Twitter: "Revealed: Merck (MRK), the US-listed pharma group, is th...

Merck 'linked' to takeover bid for Incyte, Sky News says

13:40 EST Incyte (INCY) trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try N...

Incyte trading resumes

Stocks are attempting to walk back this morning's losses tied to escalating tensions between Russia and Ukraine.

Nasdaq Reverses Losses Amid Nvidia Fanfare

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

What Moved Markets This Week

In a report released today, Marc Frahm from TD Cowen maintained a Buy rating on Incyte (INCY – Research Report), with a price target of $86.00. The...

TD Cowen Remains a Buy on Incyte (INCY)

In a report released on November 25, Brian Abrahams from RBC Capital maintained a Hold rating on Incyte (INCY – Research Report), with a price targ...

RBC Capital Sticks to Its Hold Rating for Incyte (INCY)

AAPL

AKTX

AMZN

APLS

APVO

BERY

BLNK

BNTX

CART

CHPT

CHRS

CSGP

GOOG

GOOGL

HOTH

IIIV

INTC

JNPR

JOBY

KEYS

LBRT

NVDA

ORCL

SABR

SNEJF

SNOW

SONY

TNXP

UBER

XCUR

Press Releases

Incyte Furthers Commitment to People Living with Atopic Dermatitis by Sharing Additional Patient Experiences as part of its Moments of Clarity Program

Knight Therapeutics Announces Approval of Minjuvi® (tafasitamab) in Mexico

Incyte Named One of Top 5 Companies on Science Magazine's 2024 Top Employers List

Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

Incyte to Present at Upcoming Investor Conferences

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Incyte to Present at Upcoming Investor Conference

Incyte Provides Update on Early Phase MRGPRX2 and MRGPRX4 Programs

Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting

Comments

Incyte

Incyte (INCY) Forecast

Incyte (NASDAQ:INCY) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga